Validation of amyloid PET positivity thresholds in centiloids: a multisite PET study approach

[1] Klunk WE(2004)Imaging brain amyloid in Alzheimer’s disease with Pittsburgh Compound-B Ann Neurol. 55 306-319

[2] Engler H(2009)Test-retest variability of quantitative [11C]PIB studies in Alzheimer’s disease Eur J Nucl Med Mol Imaging. 36 1629-1638

[3] Nordberg A(2013)Amyloid-β imaging with Pittsburgh compound B and florbetapir: comparing radiotracers and quantification methods J Nucl Med. 54 70-77

[4] Wang Y(2015)The influence of biological and technical factors on quantitative analysis of amyloid PET: points to consider and recommendations for controlling variability in longitudinal data Alzheimers Dement. 11 1050-1068

[5] Blomqvist G(2015)The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET Alzheimers Dement 11 1-15.e1

[6] Holt DP(2013)Research and standardization in Alzheimer’s trials: reaching international consensus Alzheimers Dement. 9 160-168

[7] Bergström M(2017)18F-Florbetaben PET beta-amyloid binding expressed in Centiloids Eur J Nucl Med Mol Imaging. 44 2053-2059

[8] Savitcheva I(2018)Standardization of amyloid quantitation with florbetapir standardized uptake value ratios to the Centiloid scale Alzheimers Dement. 14 1565-1571

[9] Huang GF(2015)Measurement of longitudinal β-amyloid change with 18F-florbetapir PET and standardized uptake value ratios J Nucl Med. 56 567-574

[10] Estrada S(2015)Improved longitudinal [(18)F]-AV45 amyloid PET by white matter reference and VOI-based partial volume effect correction Neuroimage. 108 450-459

[1] Klunk WE(2004)Imaging brain amyloid in Alzheimer’s disease with Pittsburgh Compound-B Ann Neurol. 55 306-319

[2] Engler H(2009)Test-retest variability of quantitative [11C]PIB studies in Alzheimer’s disease Eur J Nucl Med Mol Imaging. 36 1629-1638

[3] Nordberg A(2013)Amyloid-β imaging with Pittsburgh compound B and florbetapir: comparing radiotracers and quantification methods J Nucl Med. 54 70-77

[4] Wang Y(2015)The influence of biological and technical factors on quantitative analysis of amyloid PET: points to consider and recommendations for controlling variability in longitudinal data Alzheimers Dement. 11 1050-1068

[5] Blomqvist G(2015)The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET Alzheimers Dement 11 1-15.e1

[6] Holt DP(2013)Research and standardization in Alzheimer’s trials: reaching international consensus Alzheimers Dement. 9 160-168

[7] Bergström M(2017)18F-Florbetaben PET beta-amyloid binding expressed in Centiloids Eur J Nucl Med Mol Imaging. 44 2053-2059

[8] Savitcheva I(2018)Standardization of amyloid quantitation with florbetapir standardized uptake value ratios to the Centiloid scale Alzheimers Dement. 14 1565-1571

[9] Huang GF(2015)Measurement of longitudinal β-amyloid change with 18F-florbetapir PET and standardized uptake value ratios J Nucl Med. 56 567-574

[10] Estrada S(2015)Improved longitudinal [(18)F]-AV45 amyloid PET by white matter reference and VOI-based partial volume effect correction Neuroimage. 108 450-459